Haploidentical transplantation using G-CSF-mobilized T-cell replete PBSCs and post-transplantation CY after non-myeloablative conditioning is safe and is associated with favorable outcomes

Bone Marrow Transplantation

Volumn 49, Issue 8, 2014, Pages 1124-1126

  Bhamidipati, P K ^a   Dipersio, J F ^a   Stokerl Goldstein, K ^a   Rashidi, A ^a   Gao, F ^a   Uy, G L ^a   Westervelt, P ^a   Vij, R ^a   Schroeder, M A ^a   Abboud, C N ^a   Keller, J W ^a   Fehniger, T A ^a   Romee, R ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGED; ALLOGRAFT; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HEMATOLOGIC NEOPLASMS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTE DEPLETION; MALE; MIDDLE AGED; MORTALITY; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; STEM CELL MOBILIZATION; SURVIVAL RATE; TIME;

ADULT; AGED; ALLOGRAFTS; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL MOBILIZATION; HUMANS; LYMPHOCYTE DEPLETION; MALE; MIDDLE AGED; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; SURVIVAL RATE; TIME FACTORS; TRANSPLANTATION CONDITIONING;

EID: 84905685573     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2014.108     Document Type: Letter

References (8)

1. Luznik L, O'Donnell PV, Symons HJ, Chen AR, Leffell MS, Zahurak M et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant 2008; 14: 641-650.
2. Solomon SR, Sizemore CA, Sanacore M, Zhang X, Brown S, Holland HK et al. Haploidentical transplantation using T cell replete peripheral blood stem cells and myeloablative conditioning in patients with high-risk hematologic malignancies who lack conventional donors is well tolerated and produces excellent relapse-free survival: results of a prospective phase II trial. Biol Blood Marrow Transplant 2012; 18: 1859-1866.
3. Grosso D, Carabasi M, Filicko-O'Hara J, Kasner M, Wagner JL, Colombe B et al. A 2-step approach to myeloablative haploidentical stem cell transplantation: a phase 1/2 trial performed with optimized T-cell dosing. Blood 2011; 118: 4732-4739.
4. Dominietto A, Raiola AM, Bruno B, van Lint MT, Frassoni F, Grazia CD et al. Rapid immune reconstitution following unmanipulated haploidentical BMT with post-transplant high dose cyclophosphamide. ASH Annual Meeting Abstracts 2011; 118: 3050.
5. Raiola AM, Dominietto A, Ghiso A, Di Grazia C, Lamparelli T, Gualandi F et al. Unmanipulated haploidentical bone marrow transplantation and posttransplantation cyclophosphamide for hematologic malignancies after myeloablative conditioning. Biol Blood Marrow Transplant 2013; 19: 117-122.
6. Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974; 18: 295-304.
7. Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005; 11: 945-956.
8. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999; 94: 496-509